Novartis AG found using ticker (NVS) now have 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 108.5 and 103 calculating the average target price we see 105.13. Given that the stocks previous close was at 88.89 this now indicates there is a potential upside of 18.3%. There is a 50 day moving average of 87.76 while the 200 day moving average is 89.13. The market cap for the company is $201,251m. You can visit the company’s website by visiting: http://www.novartis.com
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.